Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Abstract Background Endocrine resistance is a major challenge in treating patients with ER+ /HER2− metastatic breast cancer (MBC) necessitating a switch from endocrine therapy to more toxic therapies. Mutations in ESR1 constitute a key mechanism of resistance to endocrine therapy in ER+ /HER2− BC. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Breast Cancer Research
Subjects:
Complete estrogen receptor antagonist
Selective estrogen receptor degrader
Estrogen receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer
Endocrine therapy
Palazestrant
Estrogen receptor mutation
Online Access:https://doi.org/10.1186/s13058-025-02049-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02049-y

Similar Items